Biomarkers in oncology drug development: rescuers or troublemakers?
Author:
Publisher
Informa Healthcare
Subject
Pharmacology,Toxicology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/17425255.4.11.1391
Reference34 articles.
1. Can the pharmaceutical industry reduce attrition rates?
2. Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort
3. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
4. Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
5. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The growing role of precision and personalized medicine for cancer treatment;TECHNOLOGY;2018-09
2. Preclinical Development of Oncology Drugs;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2017
3. Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer;Journal of Thoracic Oncology;2014-02
4. Preclinical Development of Oncology Drugs;A Comprehensive Guide to Toxicology in Preclinical Drug Development;2013
5. Benefit–risk management in the age of personalized healthcare;Personalized Medicine;2012-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3